The Glutamate Hypothesis: A Pathogenic Pathway from which Pharmacological Interventions have Emerged

 

 Buy Article Permissions and Reprints

Abstract

We discuss the relevance of the glutamate hypothesis in explaining cognitive disturbances and negative symptoms in schizophrenia. 4 lines of evidence support the hypothesis that glutamate deregulation, mainly through dysfunction of the N-methyl-D-aspartate (NMDA) receptor, is an important underlying mechanism of schizophrenia. Glutamate pathways are promising sites for intervention. Glutamate agonists combined with non-clozapine antipsychotics and glutamate antagonists augmented to clozapine show interesting clinical benefits in refractory schizophrenia. We illustrate how unique properties of the NMDA receptor antagonist memantine in addition to clozapine, may cause improvement of positive, negative and cognitive symptoms of schizophrenia.

• References

• 1 Buchanan RW, Davis M, Goff D et al. A Summary of the FDANIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophr Bull 2005; 31: 5-19
  CrossrefPubMedGoogle Scholar
• 2 Heaton RK, Gladsjo JA, Palmer BW et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001; 58: 24-32
  CrossrefPubMedGoogle Scholar
• 3 Javitt DC. glutamate involvement in schizophrenia: focus on N-methyl-D-aspartate receptors. Prim Psychiatry 2006; 13: 38-46
  PubMedGoogle Scholar
• 4 Stone JM, Morrison PD, Pilowsky LS. Review: glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. J Psychopharmacol 2007; 21: 440-452
  PubMedGoogle Scholar
• 5 Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409-415
  CrossrefPubMedGoogle Scholar
• 6 Schulte R. Clozapin bei therapieresistenter Schizophrenie. Plasmaspiegel und Dauer eines ausreichenden Behandlungs-versuchs. Psychopharmakotherapie 2003; 1-11
  PubMedGoogle Scholar
• 7 Loonen AJM, Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatr Scand 2010; 122: 435-437
  CrossrefPubMedGoogle Scholar
• 8 Kornmeier J, Sosic-Vasic Z. Parallels between spacing effects during behavioural and cellular learning. Front Hum Neurosci 2012; 6: 203
  PubMedGoogle Scholar
• 9 Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-1377
  CrossrefPubMedGoogle Scholar
• 10 Papanastasiou E, Stone JM, Shergill S. When the drugs don’t work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 2013; 202: 91-93
  CrossrefPubMedGoogle Scholar
• 11 Harrison PJ, Lyon L, Sartorius LJ et al. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008; 22: 308-322
  CrossrefPubMedGoogle Scholar
• 12 Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 2002; 1: 1-16
  CrossrefPubMedGoogle Scholar
• 13 Fell MJ, McKinzie DL, Monn JA et al. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012; 62: 1473-1483
  CrossrefPubMedGoogle Scholar
• 14 Allen P, Luigjes J, Howes OD et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull 2012; 38: 1268-1276
  CrossrefPubMedGoogle Scholar
• 15 Moghaddam B, Adams B, Verma A et al. Activation of glutmatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927
  CrossrefPubMedGoogle Scholar
• 16 Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2006; Issue 2. Art. No.: CD003730
  PubMedGoogle Scholar
• 17 Takata A, Iwayama Y, Fukuo Y et al. A population-specific uncommon variant in GRIN3A associated with schizophrenia. Biol Psychiatry 2013; 73: 532-539
  CrossrefPubMedGoogle Scholar
• 18 Wandinger KP, Saschenbrecker S, Soecker W et al. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011; 231: 86-91
  CrossrefPubMedGoogle Scholar
• 19 Steiner J, Walter M, Glanz W et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70: 271-278
  CrossrefPubMedGoogle Scholar
• 20 Marsman A, van den Heuvel MP, Klomp DW et al. Glutamate in Schizophrenia: A focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull 2011; 1-10
  PubMedGoogle Scholar
• 21 Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500
  CrossrefPubMedGoogle Scholar
• 22 Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 2010; 13: 2-4
  CrossrefPubMedGoogle Scholar
• 23 Jackson M, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sic USA 2004; 101: 6391-6396
  CrossrefPubMedGoogle Scholar
• 24 Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS drugs 2011; 25: 859-885
  CrossrefPubMedGoogle Scholar
• 25 Goff DC, Leahy L, Berman I et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487
  CrossrefPubMedGoogle Scholar
• 26 Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacol Sci 2009; 30: 25-31
  CrossrefPubMedGoogle Scholar
• 27 Fraley ME. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat 2009; 19: 1259-1275
  CrossrefPubMedGoogle Scholar
• 28 Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13: 1102-1107
  Google Scholar
• 29 Kinon BJ, Zhang L, Millen BA et al. HBBI Study Group . A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011; 31: 349-355
  CrossrefPubMedGoogle Scholar
• 30 Kinon B, Millen BA, Downing AC et al. LY, 2140023 monohydrate in the treatment of patients with schizophrenia: results of 2 clinical trials assessing efficacy in treating acutely ill and those with prominent negative symptoms. Schizophr Bull 2013; 39: S338
  PubMedGoogle Scholar
• 31 Adams DH, Kinon BJ, Baygani S et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 2013; 13: 143
  CrossrefPubMedGoogle Scholar
• 32 Adams DH, Zhang L, Millen BA et al. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treatment 2014; 1-11
  PubMedGoogle Scholar
• 33 Trabanco AA, Cid JM. mGluR2 positive allosteric modulators: a patent review (2009-present). Expert Opin Ther Pat 2013; 23: 629-647
  CrossrefPubMedGoogle Scholar
• 34 Hopkins CR. Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?. ACS Chem Neurosci 2013; 20: 211-213
  PubMedGoogle Scholar
• 35 Javitt DC. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophr Bull 2012; 38: 911-913
  CrossrefPubMedGoogle Scholar
• 36 Emmett MR, Mick SJ, Cler JA et al. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991; 30: 1167-1171
  CrossrefPubMedGoogle Scholar
• 37 Lane HY, Huang CL, Wu PL et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-649
  CrossrefPubMedGoogle Scholar
• 38 Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
  Google Scholar
• 39 Naheed M, Geen B. Focus on clozapine. Curr Med Res Opin 2001; 17: 223-229
  CrossrefPubMedGoogle Scholar
• 40 Howes OD, Egerton A, Allan V et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights form PET and SPECT imaging. Current Pharmaceutical Design 2009; 15: 2550-2559
  CrossrefPubMedGoogle Scholar
• 41 Yeun EY, Zhong P, Yan Z. Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. Proc Natl Acad Sci USA 2010; 107: 22308-22313
  CrossrefPubMedGoogle Scholar
• 42 Tanahashi S, Yamamura S, Nakagawa M et al. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012; 165: 1543-1555
  CrossrefPubMedGoogle Scholar
• 43 Veerman SRT, Schulte PFJ, Begemann MJH et al. Clozapine Augmented with Glutamate Modulators in Refractory Schizophrenia: A Review and Meta-analysis. Pharmacopsychiatry 2014; in press
  PubMedGoogle Scholar
• 44 Joshi I, Yang Y-M, Wang L-Y. Cellular/molecular coincident activation of metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing calyx of the held synapse. J Neurosci 2007; 27: 9989-9999
  CrossrefPubMedGoogle Scholar
• 45 Tiihonen J, Hallikainen T, Ryynänen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1241-1248
  CrossrefPubMedGoogle Scholar
• 46 Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66: 1012-1015
  CrossrefPubMedGoogle Scholar
• 47 Behdani F, Hebrani P, Rezaei Ardani A et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med 2011; 14: 270-275
  PubMedGoogle Scholar
• 48 Tsouli S, Konitsiotis S. How should we treat a patient with early Parkinson’s disease?. Int J Clin Pract 2010; 64: 1210-1219
  CrossrefPubMedGoogle Scholar
• 49 Ossola B, Schendzielorz N, Chen SH et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. Neuropharmacology 2011; 61: 574-582
  CrossrefPubMedGoogle Scholar
• 50 de Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416-1423
  CrossrefPubMedGoogle Scholar
• 51 Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56: 441-446
  CrossrefPubMedGoogle Scholar
• 52 Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 2013; 1-7
  PubMedGoogle Scholar
• 53 Angus S, Sugars J, Boltezar R et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997; 17: 88-91
  CrossrefPubMedGoogle Scholar
• 54 Silver H, Goodman C, Isakov V et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 2005; 20: 319-326
  CrossrefPubMedGoogle Scholar
• 55 Pappa S, Tsouli S, Apostolou G et al. Effects if amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010; 33: 271-275
  CrossrefPubMedGoogle Scholar
• 56 Rezaei F, Mohammad-karimi M, Seddighi S et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2013; 33: 1-7
  CrossrefPubMedGoogle Scholar
• 57 Lieberman JA, Papadakis K, Csernansky J et al. MEM-MD-29 Study Group . A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34: 1322-1329
  CrossrefPubMedGoogle Scholar
• 58 Lee JG, Lee SW, Lee BJ et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig 2012; 9: 166-173
  CrossrefPubMedGoogle Scholar
• 59 Os van J, Kahn R. Remissiecriteria voor de diagnose schizofrenie. Tijdschr Psychiatr 2007; 49: 21-26
  PubMedGoogle Scholar
• 60 Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; CD003154
  PubMedGoogle Scholar
• 61 Winblad B, Jones RW, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-27
  CrossrefPubMedGoogle Scholar
• 62 Levaux MN, Potvin S, Sepehry AA et al. Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. Eur Psychiatry 2007; 22: 104-115
  CrossrefPubMedGoogle Scholar
• 63 Guy W. Clinical Global Impression Scale. In Guy W. ECDEU Assessment Manual for Psychopharmacology- Revised. Rockville MD: US Dept. of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976. 218-222
  Google Scholar
• 64 Kay SR, Flszbein A, Opfer LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987; 13: 261-276
  Google Scholar
• 65 Baron-Cohen S, Wheelwright S, Hill J et al. The “Reading the Mind in the Eyes” Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 2001; 42: 241-251
  CrossrefPubMedGoogle Scholar
• 66 Wing J, Lelliott P, Chaplin RH. Reliability and validity of HoNOS (multiple letters). Psychiatric Bull 1999; 23: 375
  CrossrefPubMedGoogle Scholar
• 67 Priebe S, Huxley P, Knight S et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 1999; 45: 7-12
  CrossrefPubMedGoogle Scholar
• 68 Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1362-1374
  CrossrefPubMedGoogle Scholar
• 69 Muhonen LH, Lönnqvist J, Juva K et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008; 69: 392-399
  CrossrefPubMedGoogle Scholar
• 70 Stewart SE, Jenike EA, Hezel DM et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30: 34-39
  CrossrefPubMedGoogle Scholar
• 71 Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247-251
  CrossrefPubMedGoogle Scholar
• 72 Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989; 46: 1012-1016
  CrossrefPubMedGoogle Scholar
• 73 Day JC, Wood G, Dewey M et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995; 166: 650-653
  CrossrefPubMedGoogle Scholar